Clareo Health | An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy
Prostate volume estimated at 40 mL or less as determined by TRUS.
ECOG performance score 0 to 2.
Serum testosterone of at least 1 ng/dL.
You may not be if
Prior history of metastatic prostate cancer.
Salvage external beam therapy and/or salvage brachytherapy prior to enrollment.
Biological, immunological, chemotherapeutic treatment or cryotherapy after completing radiation.
Androgen ablation therapy within 12 months prior to enrollment.
Recurrence of prostate cancer within 18 months of definitive primary radiotherapy.
Other medication for prostate cancer.
Presence of active malignancy other than prostate cancer.
Treatment with other investigational therapies within 12 months prior to enrolment.
Presence of a chronic indwelling Foley catheter for obstructive uropathy.
Previous transurethral resection of the prostate (TURP), transurethral resection of the bladder neck, photo-selective vaporization of the prostate (PVP) or other resection surgery in the urinary tract.
Previous treatment with PRX302.
Any evidence of metastatic disease on bone scan, CT or magnetic resonance imaging (MRI) within 3 months prior to enrollment.
